Table 1.

Activity of immune checkpoint inhibitor in second-line non-small cell lung cancer (NSCLC)

Squamous NSCLC
Clinical trial	CheckMate 01714		KEYNOTE-01011		OAK16
Drug	Nivolumab	Docetaxel	Pembolizumab* 2–10 mg/kg	Docetaxel	Atezolizumab	Docetaxel
No. of patients	135	137	156	66	112	110
m OS	9.2	6.0	NA	NA	8.9	7.7
HR	0.62 (0.48–0.81)		0.74 (0.50–1.09)		0.73 (0.54–0.98)
1-year overall survival (OS) (%)	42	24	43/52**	35	55§	41§
2-year OS (%)	23	15	30.1a/ 37.5b§	14.5	31§	21§
3-year OS (%)	16	6

Non-squamous NSCLC
Clinical trial	CheckMate 05715		KEYNOTE-01011		OAK16
Drug	Nivolumab	Docetaxel	Pembolizumab* 2–10 mg/kg	Docetaxel	Atezolizumab	Docetaxel
No. of patients	287	268	444	240	313	315
m OS	12.2	9.5	NA	NA	15.6	11.2
HR	0.75 (0.63–0.91)		0.63 (0.50–0.79)		0.73 (0.60–0.89)
1-year OS (%)	51	39	43/52§	35§	55§	41§
2-year OS (%)	29	13	30.1a/37.5b §	14.5	31§	21§
3-year OS (%)	18	9

m OS, median overall survival.